A Double-Blind, Placebo-Controlled Dose Response Study to Investigate Pharmacodynamics and Pharmacokinetics of Single and Repeated Oral Doses of VA106483 in Elderly Male Subjects
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2013
At a glance
- Drugs Fedovapagon (Primary)
- Indications Nocturia
- Focus Pharmacodynamics; Pharmacokinetics
- 21 Jul 2012 Actual end date (2 Feb 2009) added as reported by European Clinical Trials Database record.
- 21 Jul 2012 New source identified and integrated (European Clinical Trials Database record; EudraCT2008-003774-17).
- 21 Jul 2012 Primary endpoints added as reported by European Clinical Trials Database record.